RT Journal Article
SR Electronic
T1 Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263406
DO 10.1101/2021.09.13.21263406
A1 Miller, Richard A.
A1 Guru, Pramod
A1 Bauer, Philippe
A1 Robles, Jorge
A1 Tomaszewski, Christian
A1 Overcash, J. Scott
A1 Waters, Michael
A1 Cameron, Miriam
A1 Olalla Sierra, Julián
A1 Janc, James
A1 Rudnick, Jenny A.
A1 Hu, Shenshen
A1 Jones, William B.
A1 Kwei, Long
A1 Mahabhashyam, Suresh
A1 Willingham, Stephen B.
A1 Criner, Gerard
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.13.21263406.abstract
AB Robust polyclonal humoral immune responses have the potential to generate a diverse set of antibodies to neutralize and eliminate viruses such as SARS-CoV-2 and protect against transmission, re-infection and the evolution of variants that evade immunity. CD73 is present on subsets of human B and T cells where it plays a role in lymphocyte activation and migration. CD73 also functions as an ectoenzyme that converts AMP into immunosuppressive adenosine. We have developed a humanized anti-CD73 antibody, mupadolimab (CPI-006), that blocks CD73 enzymatic activity and activates CD73POS B cells, thereby inducing differentiation into plasmablasts, immunoglobulin class switching, and antibody secretion independent of the adenosine modulatory activity. These effects suggest mupadolimab may enhance the magnitude, diversity, and duration of anti-viral responses in patients with COVID-19. This hypothesis was tested in a dose escalation phase 1 trial in 29 hospitalized patients with COVID-19. Single doses of 0.3 mg/kg – 5 mg/kg mupadolimab were well tolerated with no drug related adverse events. Doses greater than 0.3 mg/kg resulted in rapid generation of IgG and IgM to SARS-CoV-2 significantly above titers measured in convalescent controls, with elevated IgG titers sustained for more than 6 months beyond presentation of symptoms. Based on these findings, a randomized double-blind, placebo-controlled Phase 3 study in hospitalized patients was initiated. The primary endpoint was proportion of patients alive and free from respiratory failure within 28 days. This trial was discontinued early during the period of waning COVID-19 incidence after enrolling 40 patients. Although underpowered, results from this trial suggest improvement in the primary and key secondary endpoints in patients treated with single doses of 2 mg/kg and 1 mg/kg compared to placebo. The presumed mechanism of action, stimulation of B cells, may represent a novel approach to immunotherapy of COVID-19 and other viral infections.Competing Interest StatementA subset of authors (RAM, JJ, JAR, SH, WBJ, LK, SM, SBW) are employees, consultants or shareholders of Corvus Pharmaceuticals. RAM and SBW are inventors on patents owned by Corvus Pharmaceuticals related to this work. All other authors have nothing additional to disclose.Clinical TrialNCT04734873, NCT04464395Funding StatementAll studies presented here were funded by Corvus Pharmaceuticals.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western Institutional Review Board, Inc; Advarra Institutional Review Board; Mayo Clinic Institutional Review Board; Sharp HealthCare Institutional Review Board; Comité de Ética de Investigación con Medicamentos del Hospital Universitario Puerta de Hierro Majadahonda.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for resources and/or reagents should be directed to Dr. Richard A. Miller (RMiller{at}corvuspharma.com).